This segment focuses on the research, development, and commercialization of drugs targeting cardio-cerebrovascular and nervous system diseases. KPC Pharmaceuticals offers a range of products, including the Gastrodine series, designed to treat conditions related to these systems. Research and development efforts concentrate on identifying and developing new botanical drug formulations and improving existing ones. The company utilizes advanced extraction and purification techniques to ensure product efficacy and safety. This segment addresses significant patient needs by providing treatments for prevalent conditions, offering a competitive advantage through its focus on traditional Chinese medicine and botanical drugs. Future opportunities include expanding the product portfolio and exploring new therapeutic applications. Regulatory and clinical aspects involve rigorous testing and approval processes to ensure compliance and patient safety. Partnerships and collaborations may include research institutions and hospitals to facilitate clinical trials and market access.

This segment is dedicated to the development, production, and distribution of antimalarial drugs, including artemisinin-based therapies. KPC Pharmaceuticals markets artemisinin antimalarials under various brand names. Research and development efforts focus on improving the efficacy and safety of existing antimalarial drugs and exploring new formulations. The company utilizes advanced manufacturing processes to ensure high-quality products. This segment addresses a critical global health issue by providing life-saving treatments for malaria. Market positioning is enhanced by the company's expertise in botanical drugs and its presence in the Chinese market. Future opportunities include expanding into new markets and developing new antimalarial drugs. Regulatory and clinical aspects involve adherence to international standards and clinical trials to demonstrate efficacy and safety. Partnerships and collaborations may include global health organizations and research institutions to combat malaria.

This segment encompasses the research, development, manufacturing, and commercialization of traditional Chinese medicines and ethnic drugs. KPC Pharmaceuticals offers a diverse portfolio of products under brands like Luotai, Tianxuanqing, and Artemedine. Research and development activities focus on identifying and validating the therapeutic benefits of traditional herbal formulations, as well as modernizing their production. The company employs advanced extraction and formulation technologies to ensure product quality and efficacy. This segment addresses a broad range of health needs, leveraging the company's expertise in TCM. Market positioning is strengthened by its established presence in the Chinese market and its focus on natural medicines. Future opportunities include expanding the product range, exploring new therapeutic areas, and increasing international market penetration. Regulatory and clinical aspects involve compliance with Chinese and international regulations, as well as clinical trials to demonstrate efficacy and safety. Partnerships and collaborations may include TCM research institutions and hospitals.